Jacobio Pharma Secures Breakthrough Designation for Glecirasib a Pancreatic Cancer Drug
Jacobio Pharma, a company dedicated to advancing oncology treatments, has revealed a significant development. Their internally developed KRAS G12C inhibitor, named glecirasib, has received the coveted breakthrough therapy designation (BTD) from China's Center for Drug Evaluation (CDE), a division of the National Medical Products Administration (NMPA). This designation is intended for pancreatic cancer patients with a specific KRAS G12C mutation who have not responded to standard initial treatments.
The BTD was granted based on compelling clinical evidence from ongoing trials, highlighting the inhibitor's efficacy and safety profile. This recognition is expected to accelerate glecirasib's clinical progress, enabling faster access to patients in need. The upcoming pivotal clinical trial will focus on assessing the inhibitor's performance as a standalone treatment for patients with locally advanced or metastatic pancreatic cancer carrying the KRAS G12C mutation. The trial design employs a multi-center, single-arm, open-label approach.
Pancreatic cancer remains a challenging disease due to its aggressive nature and limited treatment options, with a five-year overall survival rate of just 5%, underscoring the urgent need for innovative therapies.
The Breakthrough Therapy Designation, established by the CDE, aims to expedite the development of promising drugs that offer significant clinical benefits. To qualify, a therapy must address a severe, debilitating, or life-threatening condition that lacks effective treatment or show substantial improvements over existing therapies. This designation facilitates closer guidance and collaboration with the CDE during clinical trials and development strategy discussions, and also provides the possibility of priority review in the future.
